Boehringer's bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M
Plus, news about MetaVia, NAYA Biosciences, Spruce Biosciences and Orion: Boehringer Ingelheim licenses bispecific for autoimmune diseases: The private pharma company will pay Cue Biopharma $12 million upfront ...
